Taiga Biotechnologies, Inc. is a clinical stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease and on improving blood stem cell transplantation.

Corporate History

Developing treatments for the drug resistant world
 

  • Founded in 2006 by Dr. Yosef Refaeli and Dr. Brian Turner.

  • Over $50 million in funding from Federal and State Grants and private investors.

  • US Federal Drug Administration (FDA) approved two Investigational New Drug applications (IND): Melanoma (Phase I/II) and Severe Combined Immunodeficiency (SCID) (Phase I/II).

  • FDA granted Orphan Drug Designations for two products and Rare Pediatric Drug Designation for one product.

  • Active European Medicines Agency (EMA) clinical trial: Phase I/II for enhanced engraftment of hematopoietic stem cell transplants.

  • EMA approved the Pediatric Investigational Plan for bone marrow transplant.

  • EMA granted Orphan Drug Designation to one product and Advanced Therapy Medicinal Product (ATMP) Designation to one product.

  • Israel Ministry of Health approved clinical trial protocol for solid tumors.

  • Japanese Ministry of Health, Labor and Welfare approved plan for solid tumors.

  • Headquartered in Aurora, Colorado, USA.

  • Wholly-owned subsidiaries: Taiga Biotechnologies Japan KK, Taiga Biotechnologies Europe BV, Taiga Biotechnologies Israel Ltd., Taiga Biotechnologies Singapore Pte. Ltd., SustentoBio Inc. (USA), and SustentoBio Japan KK.